🍪 The GLP Lounge uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsMASH / Liver DiseaseSurvodutide MASH Phase 2b — March 2026 Page 4

Survodutide MASH Phase 2b — March 2026

CanadaChris Fri, Aug 15, 2025 at 9:27 PM 31 replies 1,956 viewsPage 4 of 7
PeptideChemSF
Senior Member
1,890
9,012
Jan 2024
San Francisco, CA
Aug 18, 2025 at 2:09 PM#16

Adding the clinical framing, because it changes how the question reads. The mechanism and the magnitude are separate questions. Agreeing that something happens says nothing about whether it happens enough to act on.

30 3steve_okc, dave_SLC, FDA_TrackerJim and 27 others
Reply Quote Save Share Report
SurmountFan_IN
Member
789
3,456
May 2024
Indianapolis, IN
Aug 18, 2025 at 11:21 PM#17
PeptideChemSF said:
The mechanism and the magnitude are separate questions.

Second this. Posting only so the count is not one.

31 4AttorneyGrant, DebRD_ATL, KristenIndy and 28 others
Reply Quote Save Share Report
Dr.MetabolicMD
VIP Member
2,345
16,789
Jan 2024
Rochester, MN
Aug 19, 2025 at 8:33 AM#18
PeptideChemSF said:
The mechanism and the magnitude are separate questions.

Coming at PeptideChemSF’s question from a different direction. It helps to say which part of this you are uncertain about. A precise question gets a precise answer; a general one gets everybody’s favourite anecdote.

Worth separating that from liver and MASH, which this thread keeps folding into the same question. They behave differently and the advice does not transfer.

32 5HealthEcon_DC, PedsEndoPhilly, SleepDoc_PDX and 29 others
Reply Quote Save Share Report

Sigma-Aldrich — Research-Grade Standards

Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.

Shop Reference Standards
jason_paloalto
Member
212
890
Nov 2024
Palo Alto, CA
Aug 19, 2025 at 5:45 PM#19

The figures, for anyone assembling their own picture. Practical: whatever you change, write down the date and the reason. In three months the reason is what you will have forgotten, and the reason is what makes the record worth having.

Correct me if the detail matters more than I have assumed.

Last edited: Aug 19, 2025 at 10:45 PM
33 6andrew_nyc, Dr.EndoEP, GraceAZ_72 and 30 others
Reply Quote Save Share Report
mike_mod
Moderator
7,234
19,823
Nov 2023
New York
Online
Aug 20, 2025 at 2:57 AM#20

Moderator note: the sourcing question belongs in the vendor section and has been split out. Report rather than reply if it drifts again.

Last edited: Aug 20, 2025 at 4:57 AM
5 3PurityPaulOR, MaxMetOK, MounjBrad and 2 others
Reply Quote Save Share Report

Similar Threads

Survodutide MASH Phase 2b — histological improvement data9 replies
Semaglutide and MASH — liver fat reduction quantification13 replies
Non-invasive MASH biomarkers — FibroScan, ELF, FIB-4 on GLP-110 replies
ALT normalization rates on GLP-1 — pooled trial data20 replies
GLP-1 hepatoprotection — direct vs indirect mechanisms16 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register